"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
| Descriptor ID |
D000726
|
| MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
| Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 5 | 6 |
| 1998 | 7 | 2 | 9 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 3 | 4 |
| 2001 | 9 | 1 | 10 |
| 2002 | 7 | 9 | 16 |
| 2003 | 9 | 9 | 18 |
| 2004 | 9 | 5 | 14 |
| 2005 | 4 | 11 | 15 |
| 2006 | 13 | 4 | 17 |
| 2007 | 18 | 13 | 31 |
| 2008 | 9 | 7 | 16 |
| 2009 | 9 | 3 | 12 |
| 2010 | 8 | 15 | 23 |
| 2011 | 18 | 9 | 27 |
| 2012 | 11 | 11 | 22 |
| 2013 | 13 | 13 | 26 |
| 2014 | 15 | 10 | 25 |
| 2015 | 18 | 8 | 26 |
| 2016 | 17 | 7 | 24 |
| 2017 | 28 | 9 | 37 |
| 2018 | 29 | 16 | 45 |
| 2019 | 21 | 7 | 28 |
| 2020 | 20 | 21 | 41 |
| 2021 | 16 | 22 | 38 |
| 2022 | 9 | 43 | 52 |
| 2023 | 8 | 39 | 47 |
| 2024 | 13 | 20 | 33 |
| 2025 | 0 | 1 | 1 |
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2025 Jan; 9:e2400653.
-
Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 Trial. Cancer Med. 2024 Dec; 13(23):e70261.
-
Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries. JCO Glob Oncol. 2024 Nov; 10:e2400319.
-
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy. Prostate. 2025 Feb; 85(3):252-264.
-
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep. 2024 10 18; 14(1):24411.
-
Hypoxia-Associated Gene Signatures Are Not Prognostic in High-Risk Localized Prostate Cancers Undergoing Androgen Deprivation Therapy With Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025 Mar 01; 121(3):752-760.
-
Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals. Int J Radiat Oncol Biol Phys. 2025 Mar 01; 121(3):761-767.
-
Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series. Prostate. 2025 Jan; 85(1):40-47.
-
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol. 2025 Jan; 87(1):49-57.
-
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. Eur Urol. 2025 Mar; 87(3):314-323.